Beta-amyloid protein disrupting nerve cells function in a brain with Alzheimer’s disease


In November, we are spreading awareness about the devastating Alzheimer’s Disease. Alzheimer’s Disease often creeps up unnoticeably with symptoms worsening gradually over time. It mostly affects the older population; however, it can also start as early as in the person’s 40s or 50s. AD is the most widespread form of Dementia impacting both short- and long-term memory, thinking ability, mood and behavior.

Medication and therapy are available to treat some of the symptoms and to slow down cognitive decline. Even though no cure exists for AD, the research is ongoing actively.

GCT is a CNS & Neurology focused CRO with Dr. Jeffrey Apter, a Key Opinion Leader (KOL) in Alzheimer’s Disease as the president of the company. Please reach out to us at to find out about our experience in AD trials and / or to request a quote.